Novartis, Amgen and Eli Lilly are betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology.
In this article
Pharma thinks it’s found the next frontier in preventing heart attacks.
Novartis
, Amgen
and Eli Lilly
The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.
Drugmaker Eli Lilly is testing a new experimental drug that could be a game changer for treating high cholesterol.
At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other…
The Food and Drug Administration on Thursday approved Merck's Lipfendra, which some have hailed as a breakthrough in cholesterol…
The FDA has cleared Merck’s Lipfendra for patients whose artery‑clogging cholesterol remains high despite statins.
The interim Phase I trial data was only from 35 people, but results look good so far.
